Rubius Therapeutics, Inc
RUBY
RUBY was delisted on the 6th of March, 2023.
57 hedge funds and large institutions have $1.11B invested in Rubius Therapeutics, Inc in 2018 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 20 increasing their positions, 13 reducing their positions, and 10 closing their positions.
54% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 13
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
20% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 10
4% more funds holding
Funds holding: 55 → 57 (+2)
28% less capital invested
Capital invested by funds: $1.54B → $1.11B (-$430M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$15.3M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
+$12M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$4M |
| 4 |
Capital World Investors
Los Angeles,
California
|
+$3.1M |
| 5 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$2.67M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
-$3.1M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$1.88M |
| 3 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$1.49M |
| 4 |
MWNA
Marshall Wace North America
New York
|
-$1.41M |
| 5 |
LCM
Laurion Capital Management
New York
|
-$1.2M |
RUBY Hedge Fund Activity: Q4 2018 in Review
57 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Rubius Therapeutics, Inc (RUBY) for Q4 2018, worth a combined $1.11B — down 28% from $1.54B a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new RUBY positions and 10 closed out — a net gain of 2 holders — while 20 added to existing stakes and 13 trimmed.
The largest buyer was BlackRock, adding an estimated $15.3M. The largest seller was Capital International Investors, cutting an estimated $3.1M.
- 57 institutional investors held Rubius Therapeutics, Inc (RUBY) as of Q4 2018, up from 55 in Q3 2018.
- Funds reported $1.11B of Rubius Therapeutics, Inc stock for Q4 2018, down 28% quarter-over-quarter.
- 12 funds opened new Rubius Therapeutics, Inc positions in Q4 2018 and 10 closed out, a net change of +2 holders.
- The largest Rubius Therapeutics, Inc buyer in Q4 2018 was BlackRock, an estimated $15.3M added.
- The largest Rubius Therapeutics, Inc seller in Q4 2018 was Capital International Investors, an estimated $3.1M sold.
Based on aggregated 13F filings for Q4 2018.